# A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants

> **NCT04960124** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 24 (actual)

## Conditions studied

- Healthy
- Hepatic Impairment

## Interventions

- **DRUG:** JNJ-42847922

## Key facts

- **NCT ID:** NCT04960124
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-05
- **Primary completion:** 2021-11-19
- **Final completion:** 2021-11-19
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04960124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04960124, "A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04960124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*